Drug Profile

Gemcitabine prodrug - Helix BioPharma

Alternative Names: GEMCEDA™ - Helix BioPharma; Gemcitabine prodrug - Laevoroc Oncology; LR-06; LR-06B

Latest Information Update: 22 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Undisclosed Company
Developer Helix BioPharma
Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines
Mechanism of Action Antimetabolites; DNA synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Breast cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

20 May 2025 Helix BioPharma acquires Gemcitabine prodrug from Laevoroc Chemotherapy
20 May 2025 Preclinical trials in Breast cancer in Canada (PO)
20 May 2025 Preclinical trials in Ovarian cancer in Canada (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com